arrow
E

Elisabeth Livingstone

University Hospital Essen
H指数:38
被引数:7,248

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Beyond the Surface of Long-term Survival in Stage IV Melanoma: A Multicenter Cross-sectional Study

超越IV期黑色素瘤长期生存的表面:一项多中心横断面研究

2026-09-190
PRE
Melanoma of unknown primary shows an oncogenic pattern and clinical course of sun-exposed melanoma

未知原发灶黑色素瘤表现出日晒暴露型黑色素瘤的致癌模式和临床病程

2026-05-010
PRE
Real-world data on anti-PD-1 plus lenvatinib as a treatment option in pretreated advanced melanoma patients-a retrospective DeCOG study

PD-1抑制剂联合仑伐替尼作为经治晚期黑色素瘤患者治疗方案的现况数据——一项回顾性DeCOG研究

2026-03-260
PRE
Alcian blue-positive stromal phenotype in basal cell carcinoma is associated with progression on first-line hedgehog inhibitors
2026-01-160
OAAI
Melanoma of the Choroid and Ciliary Body in Children: Remission of Metastatic Melanoma of the Choroid After Treatment With Chemotherapy and Immune Checkpoint Inhibition
2025-11-011
OAAI
Real-world management of adjuvant systemic melanoma therapy: Multi-center survey of 51 DeCOG skin cancer centers

黑色素瘤辅助全身治疗的实际管理:DeCOG 皮肤肿瘤中心51个中心的调查

2025-11-010
OAAI
Exceptional therapeutic benefit of imatinib in cKIT-mutated mucosal melanoma followed by a KIT mutation loss

cKIT突变黏膜黑色素瘤中伊马替尼的显著治疗获益及其随后发生的KIT突变丢失

2025-10-250
OAAI
Advanced stage melanoma during pregnancy: recommendations from a retrospective, multicentre, registry-based study

妊娠期晚期黑色素瘤:一项回顾性、多中心、基于注册研究的建议

2025-10-070
OAAI
Avelumab plus cetuximab in patients with unresectable stage III or IV cutaneous squamous cell carcinoma: clinical activity and safety results from AliCe, a single-arm multicentre phase II DeCOG trial

阿维鲁姆单抗联合西妥昔单抗用于不可切除的III期或IV期皮肤鳞状细胞癌患者的临床活性和安全性结果:来自AliCe这一单臂多中心DeCOG II期试验的数据

2025-09-012
PRE
Low-dose total skin electron beam therapy in erythrodermic mycosis fungoides and Sézary syndrome: Results From the Prospective S-MISR Study

低剂量全身电子束照射疗法在红皮病型蕈样肉芽肿和Sézary综合征中的应用:来自前瞻性S-MISR研究的结果

2025-08-230
OAAI
Sex-specific survival in advanced metastatic melanoma – a DeCOG study on 2032 patients of the multicenter prospective skin cancer registry ADOREG

晚期转移性黑色素瘤的性别特异性生存率——一项DeCOG研究,涉及ADOREG多中心前瞻性皮肤癌登记研究的2032例患者。

2025-07-290
OA
Neoadjuvant Intralesional Targeted Immunocytokines (Daromun) in Stage III Melanoma.

新辅助病灶内靶向免疫细胞因子(Daromun)在III期黑色素瘤中的应用。

2025-07-070
PREAI
Fully volumetric body composition analysis for prognostic overall survival stratification in melanoma patients

全身成分的完全容积分析在黑色素瘤患者预后总生存期分层中的应用

2025-05-120
OA
Adverse effects of systemic advanced melanoma therapies-do BRAF/MEK inhibitors increase the incidence of mesenteric panniculitis?

系统性晚期黑色素瘤疗法的不良反应——BRAF/MEK抑制剂是否增加肠系膜脂肪炎的发病率?

2025-05-010
OA
Presence of brain metastasis differentially impacts long-term survival after first-line therapy in melanoma depending on BRAF mutation status

根据BRAF突变状态,脑转移的存在会对黑色素瘤一线治疗后的长期生存产生不同的影响

2025-02-140
OAAI
Real-world management of patients with complete response under immune-checkpoint inhibition for advanced melanoma

在免疫检查点抑制下对晚期黑色素瘤完全缓解的患者进行真实世界管理

2025-01-020
OAAI